Key takeaways
- No peptide is proven to build muscle. Human trials of CJC-1295 measured hormones, not muscle.
- Lean mass is not strength. Growth hormone raised lean mass about 2.1 kg without improving strength.
- Most muscle peptides are unapproved. The FDA lists BPC-157, TB-500, CJC-1295 and ipamorelin among substances with safety risks.
- Training and protein have the evidence. Protein supplementation added strength and fat-free mass during resistance training.
The Peptides
What Are Muscle Building Peptides?
Muscle building peptides are short chains of amino acids marketed for lean mass, strength or recovery. The peptides sold for muscle growth belong to two families that work in different ways and rest on different evidence.
- Growth hormone secretagogues. Sermorelin and CJC-1295 mimic growth hormone-releasing hormone (GHRH), explained in what is peptide therapy. Ipamorelin acts as a selective growth hormone secretagogue. All three prompt the pituitary gland to release more of the body's own growth hormone.
- Tissue-repair peptides. BPC-157 and TB-500 (a synthetic fragment of thymosin beta-4) are studied for healing injured muscle, tendon and ligament. They are peptides for muscle recovery, not growth, and a 2025 systematic review of BPC-157 found its evidence almost entirely preclinical.
Protocol Health offers sermorelin, tesamorelin, CJC-1295, ipamorelin, BPC-157 and TB-500 through physician-supervised care, so we have a commercial interest in these peptides and say so here. A third category sits outside prescription medicine: collagen peptides, which are food supplements taken by mouth and are covered in their own section below.
Mechanism
How Are Peptides Supposed to Build Muscle?
Peptides are supposed to build muscle indirectly, by raising growth hormone. The reasoning is that more growth hormone should mean more muscle, and injected growth hormone does raise lean body mass in trials.
The trial record for growth hormone itself shows why that reasoning needs testing. A systematic review of randomized trials in fit young adults found that injected growth hormone raised lean body mass by about 2.1 kg, yet strength and exercise capacity did not improve, and recipients had more soft-tissue swelling and fatigue. Lean mass on a scan is not the same as stronger muscle.
A secretagogue sits one step further back: CJC-1295 raised the body's own growth hormone and IGF-1 without any muscle outcome measured. A rise in growth hormone or IGF-1 on a lab report is a hormone result. It is not proof of muscle growth.
Evidence
Best Peptides for Muscle Growth: The Human Evidence, Peptide by Peptide
No peptide can be named the best for muscle growth on human evidence. Sermorelin comes closest, and its evidence is thin: one small trial of a sermorelin analog found lean mass rose in men only. For CJC-1295, ipamorelin, BPC-157 and TB-500, no human trial has measured muscle at all.
| Peptide | What human studies measured | Muscle result in humans | FDA status |
|---|---|---|---|
| Sermorelin (GHRH 1-29) | Night-time growth hormone, IGF-1, body composition and strength in older adults | Lean mass rose in men only in one 16-week trial of a close analog; no change on DEXA in a 6-week study | Approved as Geref, discontinued 2008; compounded sermorelin is unapproved |
| CJC-1295 | Growth hormone and IGF-1 levels in healthy adults | Not measured | Never FDA-approved for any use |
| Ipamorelin | Bowel recovery after surgery | Not measured | Never FDA-approved for any use |
| BPC-157 | Knee pain in a 12-patient chart review | Not measured; muscle-healing data are from rats | Never FDA-approved for any use |
| TB-500 | No published human exposure data identified by the FDA | Not measured; related data are from mice | Never FDA-approved for any use |
Sermorelin and GHRH analogs
Sermorelin, a GHRH analog, has the only human body-composition data in this group. In a single-blind trial of 19 adults aged 55 to 71, 16 weeks of nightly injections of a close sermorelin analog raised night-time growth hormone and IGF-1. Lean body mass increased in men only, with no other change in body composition in either sex, and sleep quality was unaffected. In a six-week study of 11 healthy men aged 64 to 76, nightly sermorelin raised growth hormone release and improved two of six strength measures, but DEXA-measured muscle and fat did not change. Both studies were small, neither enrolled younger adults who lift, and the second had no placebo group. The sermorelin guide covers this peptide in full.
CJC-1295
CJC-1295 has been tested in people for its hormone effect only; the CJC-1295 guide covers DAC versus no DAC. Two randomized, placebo-controlled trials in healthy adults aged 21 to 61 found a single injection raised average growth hormone 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days. A follow-up study in healthy men found growth hormone pulses persisted while baseline levels rose about 7.5-fold. Neither study measured muscle mass or strength.
Ipamorelin
Ipamorelin's reputation rests on animal work, as the ipamorelin guide details. The 1998 study that introduced it showed selective growth hormone release in rat pituitary cells, rats and swine. A published human trial of ipamorelin was a phase 2 study in 114 bowel-surgery patients, which tested gut recovery and found no significant difference from placebo. No human trial has tested ipamorelin for muscle.
BPC-157 and TB-500
BPC-157 and TB-500 are investigational repair peptides, and their muscle data are animal data. In rats, BPC-157 improved healing of a surgically cut quadriceps muscle. In a mouse model of muscular dystrophy, thymosin beta-4, the parent protein of TB-500, increased regenerating muscle fibers without improving strength. A 2025 systematic review of BPC-157 counted 35 preclinical studies and one clinical study, the knee-pain chart review, and found no clinical safety data. Healing an injured muscle in a rat is a different outcome from adding muscle in a healthy person. The guide to peptides for injury recovery covers the repair question.
Stacks
Best Peptide Stack for Muscle Growth: Is Stacking Supported?
No peptide stack for muscle growth has been tested in a published human trial. The two stacks discussed most often are CJC-1295 with ipamorelin and BPC-157 with TB-500, and each rests on the mechanism of its parts, not on a study of the combination.
CJC-1295 with ipamorelin pairs a GHRH analog with a ghrelin-receptor peptide to release growth hormone through two receptors. The CJC-1295 and ipamorelin guide explains the rationale and its limits. BPC-157 with TB-500 is marketed as the Wolverine Stack for recovery; the Wolverine Stack guide counts its human evidence. Combining two unapproved peptides also combines their unknowns, because no study has examined the safety of either pairing, and the FDA lists safety concerns for each component.
Fat Loss
Peptides for Muscle Growth and Fat Loss: Two Separate Questions
Peptides for muscle growth and fat loss are often sold as one promise, but the evidence for each goal is separate. Growth hormone shifts body composition on a scan, and that is the source of the claim. In the sermorelin-analog trial, lean mass rose in men while fat mass did not change.
One GHRH peptide does hold an FDA approval related to fat: tesamorelin (Egrifta) is approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, on the strength of trials in that population. That approval does not cover muscle building or general weight loss; use outside that indication is off-label, and a compounded tesamorelin is not FDA-approved. Fat loss has its own evidence and its own options, covered in the guide to the best peptides for weight loss.
Oral Peptides
Oral Peptides for Muscle Growth: Collagen Peptides Are a Different Category
Oral peptides for muscle growth are, in practice, collagen peptides: a protein supplement, not a prescription drug. Sermorelin, CJC-1295 and ipamorelin are prescribed as injections, not pills, and their human trials used injections.
Collagen peptides do have a human trial with a muscle outcome. In a randomized, placebo-controlled trial of 53 older men with sarcopenia, 12 weeks of resistance training plus daily collagen peptides increased fat-free mass and quadriceps strength more than training plus placebo. Every participant trained three times a week, the men averaged 72 years with age-related muscle loss, and one author worked for a collagen research institute. The result supports protein alongside training in that group. It does not transfer to injectable peptides or to younger adults.
Before and After
Peptides for Muscle Growth Before and After: What to Expect
Before-and-after photos of peptides for muscle growth are not evidence, because training, diet, lighting and other drugs change a photo more than a secretagogue is known to. No trial provides a timeline for visible muscle gain from any peptide in this article.
The published timelines describe hormones. Growth hormone and IGF-1 rose within days in the CJC-1295 trials and within two weeks in the sermorelin-analog trial. Patients often seek faster recovery, better sleep and easier muscle gain; controlled human trials have not confirmed these outcomes. A realistic expectation is a measurable change in lab values, with any change in muscle depending mostly on training and nutrition.
Safety
Are Muscle Peptides Safe? Side Effects and FDA Status
Muscle peptides are not established as safe, because none has long-term human safety data for this use, so their side effects and FDA status are what can be stated. The safest peptides for muscle growth cannot be ranked from trials; what can be stated is each peptide's regulatory status and the risks the FDA has named.
- Sermorelin. Sermorelin was FDA-approved as Geref in 1990 as a diagnostic and in 1997 for growth hormone deficiency in children. Its maker discontinued it in 2008, and in 2013 the FDA determined that Geref was not withdrawn for reasons of safety or effectiveness. Sermorelin prescribed today is compounded, and compounded sermorelin is unapproved.
- BPC-157, TB-500, CJC-1295 and ipamorelin. These four peptides have never been FDA-approved for any use. On the FDA list of bulk drug substances that may present significant safety risks (content current as of 04/22/2026), BPC-157, TB-500 and CJC-1295 appear as nominated but withdrawn, and ipamorelin remains in 503B Category 2.
- Named risks. For all four, the FDA cites possible immune reactions (immunogenicity) and peptide-related impurities. It also reports serious adverse events with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and says it has identified no human exposure data for TB-500. For ipamorelin, it cites a published study reporting serious adverse events, including death, with intravenous use.
- Sport. The World Anti-Doping Agency prohibits these peptides in sport, in and out of competition. Tested athletes should not use them.
The most commonly reported side effects of sermorelin are transient facial flushing and injection-site pain (1999 review); headache and fluid retention are also described in clinical use. The 16-week sermorelin-analog trial recorded a temporary rise in blood lipids. People with active cancer or a history of certain cancers, and anyone pregnant or breastfeeding, are generally not candidates. Gray-market vials sold online add contamination and labeling risks on top of the unknowns of the molecules themselves; see our safety information. In short, no muscle peptide has a proven safety record, and its FDA status and named risks are the facts to weigh with a physician.
What Builds Muscle
What Builds Muscle: Training, Protein and Hormones Versus Peptides
Resistance training builds muscle: a meta-analysis of 49 studies in adults over 50 found it added about 1.1 kg of lean mass, and a meta-analysis of protein supplementation found protein added strength and fat-free mass on top of training. No peptide in this article has outperformed that foundation in a human trial, and none has been tested as a substitute for it. In bodybuilding, a peptide is at most a small addition to a program that already has to be in place.
Hormones matter when they are measurably low, and signs of low testosterone are a reason to test. For men with lab-confirmed low testosterone and symptoms, treatment has direct human evidence for lean mass, which the article on testosterone and building muscle after 40 reviews. A plateau has many causes, and labs plus a body composition scan separate a hormone problem from a training or nutrition problem before any prescription is discussed.
Our Approach
Peptide Therapy for Muscle Growth at Protocol Health
Peptide therapy for muscle growth at Protocol Health starts with the Protocol Health peptide consultation: a physician reviews your history, training, goals and baseline labs before discussing any peptide. Protocol Health sees patients in person in Scarsdale, NY, and by telehealth in New York, New Jersey, Connecticut, Florida and California. If a peptide is appropriate, the physician sets the plan and the monitoring; if labs point elsewhere, the plan follows the labs. The peptide therapy page lists what the clinic offers.
Compounded peptides are not FDA-approved, so the physician weighs that before any prescription. Start with the two-minute health quiz. Peptide therapy for muscle growth at Protocol Health is a supervised, lab-led option, not a promise of muscle.
Bottom Line
The Bottom Line
Peptides for muscle growth raise hormone levels in trials but have not been shown to build muscle in healthy adults.
- Hormones are not muscle. CJC-1295 raised growth hormone 2- to 10-fold with no muscle outcome measured.
- Sermorelin has the thinnest real data. Lean mass rose in men only in one small analog trial.
- Even growth hormone disappoints. It raised lean mass without improving strength in fit young adults.
- Repair peptides are animal science. BPC-157 has 35 preclinical studies and one clinical study.
- Training still wins. Resistance exercise added about 1.1 kg of lean mass in adults over 50.
FAQ
Frequently Asked Questions
What is the best peptide for muscle growth?
No peptide has been shown to build muscle in healthy adults in a randomized controlled trial, so none can be named the best peptide for muscle growth. Sermorelin has the most human body-composition data: one small trial of a close analog found lean mass rose in older men only. CJC-1295 trials measured hormone levels, not muscle.
Do peptides for muscle growth actually work?
Peptides for muscle growth raise hormones, but whether that produces more muscle or strength is unproven. Sermorelin and CJC-1295 raised growth hormone and IGF-1 in human studies. Trials of growth hormone itself in fit young adults raised lean body mass without improving strength, and no peptide trial has tested muscle gain in people who train.
Are peptides for muscle growth FDA-approved?
No, BPC-157, TB-500, CJC-1295 and ipamorelin have never been FDA-approved for any use, and the FDA lists safety risks for them in compounding. Sermorelin was approved as Geref and discontinued for reasons other than safety; the sermorelin prescribed now is compounded and unapproved. The World Anti-Doping Agency prohibits these peptides in sport.
What are the side effects of peptides for muscle growth?
The most commonly reported side effects of sermorelin are transient facial flushing and injection-site pain. The FDA has flagged BPC-157, TB-500, CJC-1295 and ipamorelin for possible immune reactions and impurities, and has reported serious adverse events with CJC-1295, including increased heart rate. Long-term safety for muscle-building use has not been studied.
How long do peptides take to build muscle?
No trial gives a timeline for muscle gain from peptides. Growth hormone and IGF-1 rise within days to two weeks in published studies, but hormone changes are not muscle changes. In a six-week study of older men, sermorelin did not change DEXA-measured muscle.
Can women use peptides to build muscle?
Women's responses to these peptides appear to differ by sex. In the 16-week trial of a sermorelin analog, lean body mass increased in men but not in women, even though growth hormone rose in both. No trial has tested these peptides for muscle growth in women who train, and they are not used during pregnancy or breastfeeding.
Can I get peptide therapy for muscle growth through telehealth?
Yes, peptide therapy consults are available by telehealth for patients in New York, New Jersey, Connecticut, Florida and California, and in person in Scarsdale, NY. Care starts with a physician consult and baseline labs. Whether any peptide is appropriate is decided case by case.
Explore
Related at Protocol Health
Book a peptide consultationMedical disclaimer
This article is for education only and is not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, stopping, or changing any medication.
Important safety information
References
- Raun K et al., 1998. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PMID 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Vasireddi N et al., 2025. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. PMID 40756949. https://pubmed.ncbi.nlm.nih.gov/40756949/
- Liu H et al., 2008. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med. PMID 18347346. https://pubmed.ncbi.nlm.nih.gov/18347346/
- Teichman SL et al., 2006. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. PMID 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Khorram O et al., 1997. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. PMID 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
- Vittone J et al., 1997. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. PMID 9005976. https://pubmed.ncbi.nlm.nih.gov/9005976/
- Ionescu M, Frohman LA, 2006. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. PMID 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
- Beck DE et al., 2014. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. PMID 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/
- Staresinic M et al., 2006. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res. PMID 16609979. https://pubmed.ncbi.nlm.nih.gov/16609979/
- Spurney CF et al., 2010. Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. PLoS One. PMID 20126456. https://pubmed.ncbi.nlm.nih.gov/20126456/
Show all 19 references
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Falutz J et al., 2007. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. PMID 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Zdzieblik D et al., 2015. Collagen peptide supplementation in combination with resistance training improves body composition and increases muscle strength in elderly sarcopenic men: a randomised controlled trial. Br J Nutr. PMID 26353786. https://pubmed.ncbi.nlm.nih.gov/26353786/
- Federal Register, 2013. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams
- World Anti-Doping Agency. The Prohibited List. https://www.wada-ama.org/en/prohibited-list
- Prakash A, Goa KL, 1999. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. PMID 18031173. https://pubmed.ncbi.nlm.nih.gov/18031173/
- Peterson MD et al., 2011. Influence of resistance exercise on lean body mass in aging adults: a meta-analysis. Med Sci Sports Exerc. PMID 20543750. https://pubmed.ncbi.nlm.nih.gov/20543750/
- Morton RW et al., 2018. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. Br J Sports Med. PMID 28698222. https://pubmed.ncbi.nlm.nih.gov/28698222/
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Why trust our physicians
Every article is reviewed by a licensed physician on our medical team and is kept current by our editorial team. Read our editorial policy and our medical review process.
- Medically reviewed by
- Richard Dentico, MD on
- Written by
- Protocol Health Editorial Team
- First published
- Last updated
See an error? Email care@protocolhealthmd.com and we will review it.
More on Growth Hormone Peptides
- Ipamorelin Side Effects: What the Evidence Shows and Who Should Avoid It
- Ipamorelin vs Tesamorelin: What the Evidence Shows
- Tesamorelin Before and After: The Numbers the Trials Recorded
- MOTS-c Peptide: Benefits, Side Effects, and What the Evidence Shows
